40,000
35,000
30,000
25,000
20,000
10,000
0
25,986
FY 20
32,375
FY 21
37,649
FY 22
Revenue
35%
30%
25%
15%
10%
5%
0%
20.2%
FY 20
26.4%
FY 21
19.2%
FY 22
EBITDA %
9,000
7,500
6,000
4,500
3,000
1,500
0
5,253
FY 20
8,552
FY 21
7,222
FY 22
EBITDA
7,000
6,000
5,000
3,000
2,500
2,000
0
3,355
FY 20
5,495
FY 21
4,128
FY 22
PAT
23%
19%
14%
9%
6%
3%
0%
12.9%
FY 20
17.0%
FY 21
11.0%
FY 22
PAT%
26,000
22,000
18,000
15,000
10,000
5,000
0
18,437
FY 20
21,733
FY 21
25,871
FY 22
Networth
30,000
25,000
20,000
15,000
10,000
5,000
0
18,752
FY 20
21,302
FY 21
24,395
FY 22
Gross Block
Break-up of Consolidated Revenue as per Geography
FY'22 (Rs. in Mn)19,542
52%
7,902
21%
3,811
10%
4,415
12%
1,979
5%
North America
Europe
Row
Latin America
India
Break-up of Consolidated Revenue as per Business Segment
FY'22 (Rs. in Mn)19,442
52%
9,751
26%
8,456
22%
PFI
API
FD
Break-up of Consolidated Revenue as per Molecule
FY'22 (Rs. in Mn)14,282
38%
9,410
25%
4,768
13%
1,100
3%
1,114
3%
6,974
19%
Paracetamol
Metformin
Guaifenesin
Ibuprofen
Methocarbamol
Others
Break-up of Consolidated Revenue as per Business Segment
FY'20 (Rs. in Mn)13,602
52%
8,170
31%
4,214
16%
API
PFI
FD
